Abbott Laboratories (ABT) Q3 2020 Earnings Results

Abbott Labs Beats on EPS, Stock Down 2.24%

Abbott Labs reported better-than-expected earnings per share, indicating resilience in its operations. However, the stock fell by 2.24%, likely reflecting investor concerns about the lack of revenue details and future guidance. The market may be cautious as it awaits more comprehensive financial insights in upcoming reports.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$0.98	N/A	+8.65%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Overall, management expressed confidence in the company's ability to navigate current market conditions. They noted the importance of maintaining operational efficiency.

Management highlighted strong performance in key segments despite ongoing market challenges.

They emphasized a focus on innovation and product development moving forward.

Abbott Labs Beats on EPS, Stock Down 2.24%

Key numbers

Management commentary

Abbott Laboratories

More earnings this week

Abbott Labs Beats on EPS, Stock Down 2.24%

Key numbers

Management commentary